The specter of generic rivalry has long loomed over copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the prospects of similar medicinal ventures. While first years saw impressive gains, the exclusivity end has created the way for discounted alternatives, potentially lowering profitability and creating a genuine hazard for st